We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
Read MoreHide Full Article
Recursion Pharmaceuticals (RXRX - Free Report) closed the latest trading day at $8.84, indicating a +0.57% change from the previous session's end. This move lagged the S&P 500's daily gain of 1.26%. Meanwhile, the Dow experienced a rise of 1.18%, and the technology-dominated Nasdaq saw an increase of 1.99%.
The biotechnology company's stock has climbed by 0.69% in the past month, exceeding the Medical sector's loss of 1.54% and the S&P 500's loss of 2.68%.
Market participants will be closely following the financial results of Recursion Pharmaceuticals in its upcoming release. The company plans to announce its earnings on May 9, 2024. The company is predicted to post an EPS of -$0.43, indicating a 26.47% decline compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $13.36 million, indicating a 10.1% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.63 per share and revenue of $45.75 million, which would represent changes of -3.16% and +2.63%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Recursion Pharmaceuticals. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, Recursion Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 44% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow RXRX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
Recursion Pharmaceuticals (RXRX - Free Report) closed the latest trading day at $8.84, indicating a +0.57% change from the previous session's end. This move lagged the S&P 500's daily gain of 1.26%. Meanwhile, the Dow experienced a rise of 1.18%, and the technology-dominated Nasdaq saw an increase of 1.99%.
The biotechnology company's stock has climbed by 0.69% in the past month, exceeding the Medical sector's loss of 1.54% and the S&P 500's loss of 2.68%.
Market participants will be closely following the financial results of Recursion Pharmaceuticals in its upcoming release. The company plans to announce its earnings on May 9, 2024. The company is predicted to post an EPS of -$0.43, indicating a 26.47% decline compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $13.36 million, indicating a 10.1% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.63 per share and revenue of $45.75 million, which would represent changes of -3.16% and +2.63%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Recursion Pharmaceuticals. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, Recursion Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 44% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow RXRX in the coming trading sessions, be sure to utilize Zacks.com.